Ischemic Optic NeuropathyDiagnostics and screeningVision and hearingDevice
What this study is
This study investigates a new technology to assess the structure and function inside the eye. Retinal imaging of subjects with inner and outer retinal defects to detect areas of abnormal structure and function compared to other visual function tests.
What's being tested
- LSFG-NAVI
Intervention · DEVICE
laser-speckle blood flow of ocular arteries and veins
Study details
- Official title
- New Non-invasive Modalities for Assessing Retinal Structure and Function:Preliminary Investigation
- Sponsor
- Randy Kardon
- Conditions
- Ischemic Optic Neuropathy · Branch Retinal Artery Occlusion · Hemianopia · Leber Hereditary Optic Neuropathy · Acute Zonal Occult Outer Retinopathy
- Enrolling
- 500 people
- Starts
- 2019-05-06
- Est. completion
- 2028-03-01
- Design
- Open-label, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 99 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Controls:
- Normal eye exam in last 2 years
- Defined structural defect to include those with Ischemic optic neuropathy, branch retinal artery occlusion (BRAO), hemianopia or visual field defect that respects the vertical meridian, inherited mitochondrial optic neuropathies such as Leber's and Dominant Optic Neuropathy, other retinopathies or optic neuropathies.
- AZOOR (acute zonal occult outer retinopathy) or other focal or diffuse outer photoreceptor loss of function
You can't join if
- Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are okay. Any abnormalities of the retina or optic nerve that could affect metabolism of the retina outside of normal.
- Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are okay.
- Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are okay.
- The 450 total is to allow for exclusion of some subjects or in the event that the enrolled subject blinks too much or cannot fixate on a visual target adequately to maintain the same eye position during the short imaging interval. We hope to have a total of 450 (50 controls and 400 patients)
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openUniversity of Iowa Department of Ophthalmology
Iowa City, Iowa, United States
- Denise L Rettig, MHA. MBA · Contact319-356-2866 ext. 5849denise-rettig@uiowa.edu
Recruiting
Study team
Sponsor
Randy Kardon
Study ID 201611825
Principal investigator
Randy H Kardon, MD, PhD
University of Iowa Department of Ophthalmology
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.